Brief: BiomX Obtains Option To Acquire Control Of Israeli Laser-Radar Counter-Drone System
Brief: Biomx Adds Former Mossad Deputy To Advisory Board
Brief: Biomx Inc - Jonathan Solomon Resigns As CEO And Board Member Effective March 4, 2026 - SEC Filing
Brief: BiomX Says Unaware of Any Undisclosed Developments Amid Unusual Stock Trading
Brief: BiomX Announces Discontinuation Of Phase 2b Bx004 Trial Following Internal Review
Brief: BiomX Provides A Program Update And Announces New FDA Feedback Potentially Expanding BX004 Development Pathways
BiomX falls after US FDA places genetic disorder treatment study on hold
Brief: BiomX Reports Second Quarter 2025 Financial Results
Brief: Biomx Reports First Quarter 2025 Financial Results
Brief: BiomX Announces Positive Topline Results From Phase 2 Trial Evaluating Bx211 For The Treatment Of Diabetic Foot Osteomyelitis (DFO)
Brief: BiomX Announces Mandatory Unit Separation
Brief: Biomx To Provide Latest Update On Positive Phase 1B/2A Clinical Trial Data For Bx004 At North American Cystic Fibrosis Conference
Brief: Biomx Inc. Receives Notice Of Non-Compliance With NYSE American Continued Listing Standards
Brief: BiomX Reports First Quarter 2024 Financial Results And Provides Business And Program Updates
Brief: Biomx On April 11, Increased The Size Of The Board To Eight Members
Brief: Biomx Announces Closing Of The Acquisition Of Adaptive Phage Therapeutics And Concurrent $50 Million Financing
U.S. RESEARCH ROUNDUP-Highpeak Energy, Nordstrom, Victoria's Secret & Co
Brief: BiomX To Merge With Biotechnology Company Adaptive Phage Therapeutics
Brief: Biomx Inc Entered Into An At The Market Offering Agreement